Evidence map›Paper›PMID 34070094›Full record

ArticleCancers2021

CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM).

Anja Kathrin Wege, Tobias F Dreyer, Attila Teoman, Olaf Ortmann, Gero Brockhoff, Holger Bronger

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Spinal Cord Stimulation Increases Chemoefficacy and Prevents Paclitaxel-Induced Pain via CX3CL1.Neuromodulation : journal of the International Neuromodulation Society · 2023
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anja Kathrin WegeDepartment of Gynecology and Obstetrics, University Cancer Center Regensburg, 93053 Regensburg, Germany.ORCID 0000-0002-8838-0532
Tobias F DreyerDepartment of Gynecology and Obstetrics, Technical University of Munich, 81675 Munich, Germany.
Attila TeomanDepartment of Gynecology and Obstetrics, University Cancer Center Regensburg, 93053 Regensburg, Germany.
Olaf OrtmannDepartment of Gynecology and Obstetrics, University Cancer Center Regensburg, 93053 Regensburg, Germany.
Gero BrockhoffDepartment of Gynecology and Obstetrics, University Cancer Center Regensburg, 93053 Regensburg, Germany.
Holger BrongerDepartment of Gynecology and Obstetrics, Technical University of Munich, 81675 Munich, Germany.

Funding

Deutsche Forschungsgemeinschaft WE 3606/3-1 & BR4733/2-1
6 · The paper itself

Abstract

CX3CL1 is a multifunctional chemokine that is involved in numerous biological processes, such as immune cell attraction and enhanced tumor immune cell interaction, but also in enhancing tumor cell proliferation and metastasis. The multifarious activity is partially determined by two CX3CL1 isoforms, a membrane-bound and a soluble version generated by proteolytic cleavage through proteases. Here, we investigated the impact of CX3CL1 overexpression in MDA-MB-453 and SK-BR-3 breast cancer cells. Moreover, we evaluated the therapeutic capacity of Matrix-Metalloproteinases-inhibitors TMI-1 and GI254023X in combination with the anti-HER2 antibody trastuzumab in vitro and in vivo. TMI-1 and GI254023X caused a reduced shedding of CX3CL1 and of HER2 in vitro but without effects on tumor cell proliferation or viability. In addition, trastuzumab treatment did not retard MDA-MB-453 cell expansion in vitro unless CX3CL1 was overexpressed upon transfection (MDA-MB-453

Indexed as

ADAM10ADAM17breast cancerCX3CL1HER2humanized tumor mice (HTM)trastuzumab

Identifiers

PMID34070094
PMCPMC8158361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.